

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-043US1	Application No. 10/561,071
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit 1624

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/B.C./	A1	US 3652543	3/28/72	Hoegerle	540	594	
/B.C./	A2	US 3716639	2/13/73	Hoegerle et al.	514	217.01	
/B.C./	A3	US 3795683	3/05/74	Brossi et al.	540	586	
/B.C./	A4	US 4108989	8/22/78	Holden	514	217.01	
/B.C./	A5	US 4111957	9/05/78	Holden et al.	540	594	
/B.C./	A6	US 4210749	7/01/80	Shetty	540	594	
/B.C./	A7	US 4210729	7/01/80	Bola V. Shetty	525	247	
/B.C./	A8	US 4233217	11/11/80	Shetty	540	594	
duplicate							
/B.C./	A9	US 4387685	2/07/85	Powell et al.			
/B.C./	A10	US 4762845	8/09/88	Chu et al.	514	312	
/B.C./	A11	US 4988690	1/29/91	Effland et al.	514	217.01	
/B.C./	A12	US 5015639	5/14/91	Berger et al.	514	210.21	
/B.C./	A13	US 5178786	1/12/93	Jahnke et al.	252	77	
/B.C./	A14	US 5387685	7/16/93	Powell et al.	546	143	
/B.C./	A15	US 5275915	1/04/94	Kojima et al.	430	264	
/B.C./	A16	US 5412119	5/02/95	Brussee et al.	549	419	
/B.C./	A17	US 5422355	6/06/95	White et al.	514	311	
/B.C./	A18	US 5691362	11/25/97	McCormick et al.	514	339	
/B.C./	A19	US 5750520	5/12/98	Danilewicz et al.	514	212	
/B.C./	A20	US 5856503	1/05/99	Aebi et al.	548	207	
/B.C./	A21	US 5861393	1/19/99	Danilewicz et al.	514	213	
/B.C./	A22	US 5925651	7/20/99	Hutchinson	514	307	
/B.C./	A23	US 5939415	8/17/99	Laufer et al.	514	224.2	
/B.C./	A24	US 5942535	8/24/99	Laufer et al.	514	413	
/B.C./	A25	US 5958943	9/28/99	Laufer et al.	514	299	
/B.C./	A26	US 6087346	7/11/00	Glennon et al.	514	65	
duplicate							
/B.C./	A27	US 6218305	4/17/01	Adum et al.			

Examiner Signature /Brenda Coleman/	Date Considered 09/22/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-043US1	Application No. 10/561,071
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit 1624
(37 CFR §1.98(b))			

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/B.C./	A28	US 6218385	4/17/01	Geo Adam et al.	514	217.01	
/B.C./	A29	US 6900313	5/31/05	Wasserscheid et al.	544	59	
/B.C./	A30	US 6953787	10/11/05	Smith et al.	514	212.02	
/B.C./	A31	US 6972295	12/06/05	Hagmann et al.	514	345	

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
** /B.C./	A32	DE 1944121	3/19/70	Germany				
** /B.C./	A33	CH 500194	1/29/71	Switzerland				
/B.C./	A34	GB 1221324	2/03/71	United Kingdom				
/B.C./	A35	GB 1225053	3/17/71	United Kingdom				
/B.C./	A36	GB 1268243	3/22/72	United Kingdom				
** /B.C./	A37	NL 7807819	7/21/78	Netherlands				
/B.C./	A38	EP 0007070	1/23/80	Europe				
/B.C./	A39	CA 1090797	12/02/80	Canada				
/B.C./	A40	GB 1599705	10/07/81	United Kingdom				
/B.C./	A41	EP 0080779 A1	6/08/83	Europe				
** /B.C./	A42	DE 3315106 A1	11/03/83	Germany				
/B.C./	A43	EP 0096838 A1	12/28/83	Europe				
/B.C./	A44	EP 0161350 A1	11/21/85	Europe				
/B.C./	A45	EP 0174118 A2	3/12/86	Europe				
/B.C./	A46	EP 0285287 A3	3/23/87	Europe				
/B.C./	A47	EP 0285919	10/12/1988	Europe				
/B.C./	A48	WO 8807858	10/20/88	WIPO				
/B.C./	A49	WO 9119698	12/26/91	WIPO				
/B.C./	A50	WO 9300094	1/07/93	WIPO				
** /B.C./	A51	JP 5339263	12/21/93	Japan				

Examiner Signature /Brenda Coleman/	Date Considered 09/22/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-043US1	Application No. 10/561,071
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit 1 624
(37 CFR §1.98(b))			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
** /B.C./	A52	JP 06298746	10/25/94	Japan				
/B.C./	A53	WO 9513274	5/18/95	WIPO				
/B.C./	A54	CA 2197789	8/16/95	Canada				
** /B.C./	A55	WO 9604271	2/15/96	WIPO				
** /B.C./	A56	WO 9605194	2/22/96	WIPO				
** /B.C./	A57	JP 08134048	5/28/96	Japan				
/B.C./	A58	WO 9633993	10/31/96	WIPO				
	A59	JP 09030966	2/04/97	Japan				
	A60	JP 09087258	3/31/97	Japan				
/B.C./	A61	WO 97/24364	7/10/97	WIPO				
/B.C./	A62	WO 9806701	2/19/98	WIPO				
/B.C./	A63	WO 9840385	9/17/98	WIPO				
/B.C./	A64	WO 99/24411	5/20/99	WIPO				
	A65	EP 0907235 A1	3/22/00	Europe		duplicate		
/B.C./	A66	EP 1074549 A2	2/07/01	Europe				
/B.C./	A67	WO 0240471	5/23/02	WIPO				
/B.C./	A68	WO 0248124	6/20/02	WIPO				
** /B.C./	A69	WO 02074746	9/26/02	WIPO				
/B.C./	A70	WO 03000663	1/03/03	WIPO				
/B.C./	A71	WO 2003/027068	4/03/03	WIPO				
/B.C./	A72	WO 2003/062392	7/31/03	WIPO				
/B.C./	A73	WO 03086306	10/23/03	WIPO				
/B.C./	A74	EP 987235	12/03/03	Europe				
/B.C./	A75	WO 04037788	5/06/04	WIPO				
/B.C./	A76	WO2005/019179A2	03/03/2005	PCT				
/B.C./	A77	WO2005/042490A1	05/12/2005	PCT				
/B.C./	A78	WO2005/042491A1	05/12/2005	PCT				

Examiner Signature /Brenda Coleman/	Date Considered 09/22/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-043US1	Application No. 10/561,071
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit 1 6 2 4
(37 CFR §1.98(b))			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/B.C./	A79	WO 2006/013209	2/09/06	WIPO				
** /B.C./	A80	WO 2006/043710	4/27/06	WIPO				
/B.C./	A81	WO2006/069363A2	06/29/06	WIPO				
/B.C./	A82	WO2006/071740A2	07/06/06	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/B.C./	A83	Barnes, T. R., "Pharmacological Strategies for Relapse Prevention in Schizophrenia", <i>Psychiatry</i> 3(10): 37-40 (2004)
/B.C./	A84	Chahal et al., IDdb Meeting Report 2000, May 17-18
/B.C./	A85	Chang et al., "Dopamine receptor binding properties of some 2, 3, 4, 5-tetrahydro-1H-3-benzazapine-7-ols with non-aromatic substituents in the 5-position", <i>Bioorg. Med. Chem. Lett.</i> 2:399-402 (1992)
/B.C./	A86	Deady et al., "Synthesis of some tetrahydro-2- and 3-benzazepines, and of hexahydro-3-benzazocine", <i>Journal of the Chemical Society, Perkins Transactions</i> 1, 1973 pp. 782-783
/B.C./	A87	Di Chiara G., (2002) <i>Behavioural Brain Research</i> , 137: 75-114
/B.C./	A88	Di Chiara et al., "Reward System and Addiction: What Dopamine Does and Doesn't Do", <i>Current Opinion in Pharmacology</i> 7:69-76 (2007)
	A89	Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision, Washington, DC: American Psychiatric Association, 2000*
/B.C./	A90	Di Matteo et al., "Role of 5-HT _{2C} Receptors in the Control of Central Dopamine Function", <i>Trends in Pharmacological Sciences</i> 22(5):229-232 (2001)
/B.C./	A91	Flannery-Schroeder, E. C., "Reducing Anxiety to Prevent Depression", <i>Am. J. Prev. Med.</i> 31(6S1):S136-S142 (2006)
/B.C./	A92	Fuchs et al., "Total synthesis of (+/-)-lennoxamine and (+/-)-aphanorphine by intramolecular electrophilic aromatic substitution reactions of 2-amidoacroleins", <i>Organic Letters</i> , 2001, pp. 3923-3925, 3(24) American Chemical Society
/B.C./	A93	Gallant et al., (1967) <i>Current Therapy Research</i> 9(11):579-81
** /B.C./	A94	Gardent et al., "Sur quelques de l' amino-2-bromo-4 1H benzazepine-3 et de ses derives", <i>Bull Soc. Chim. France</i> 2:600-605 (1968)
/B.C./	A95	Gerace et al., "Predictors of Weight Increases over 7 Years in Fire Fighters and Paramedics", <i>Preventive Medicine</i> 94:593-600 (1996)
/B.C./	A96	Gobert et al., (2000) <i>Synapse</i> 36: 205-221
/B.C./	A97	Gombar et al., "Pharmacokinetics of a series of 6-chloro-2, 3, 4, 5-tetrahydro-3-substituted-1H-3-benzazepines in rats", <i>Drug Metab. Disposition</i> 16:367-372 (1988)
	A98	Greene et al., Protective Groups in Organic Synthesis, 2nd Ed., Wiley and Sons, NY (1991)*

Examiner Signature /Brenda Coleman/	Date Considered 09/22/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

** Structures only

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-043US1	Application No. 10/561,071
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit 1.624
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/B.C./	A99	Halford et al., "Serotonergic Drugs: Effects on Appetite Expression and Use for the Treatment of Obesity", <i>Drugs</i> 67(1):27-55 (2007)
/B.C./	A100	Halford, J.C.G., "Obesity Drugs in Clinical Development", <i>Current Opinion in Investigational Drugs</i> 7(4):312-318 (2006)
** /B.C./	A101	Hassine-Coniac et al., "Préparation et propriétés d'aldéhydes dans la série de la benzazapine-3", <i>Bull. Soc. Chim. France</i> 11:3985-3992 (1971)
** /B.C./	A102	Hazebroucq, "Accès à des 1-H, tétrahydro-2, 3, 4, 5 benzazépines-3-one-1 et à des hexahydroimidazo isouquinoléines", <i>Ann. Chim.</i> (1966) pp. 221-254
/B.C./	A103	Hester et al., (1968) <i>J. Med. Chem.</i> 11(1): 101
/B.C./	A104	Higgins et al., (2003) <i>European Journal of Pharmacology</i> , 480: 151
/B.C./	A105	Hitzig, P., (1994) <i>Journal of Substance Abuse Treatment</i> , 11(5): 489
/B.C./	A106	Im et al., (2003) <i>Molecular Pharmacology</i> , 64: 78-84
/B.C./	A107	Jandacek, R.J., "APD-356 (Arena)", <i>Current Opinion in Investigational Drugs</i> 6(10):1051-1056 (2005)
/B.C./	A108	Jenck et al., (1998) <i>European Neuropsychopharmacology</i> 8: 161 (Abstract)
/B.C./	A109	Jensen et al., "Potential Role of New Therapies in Modifying Cardiovascular Risk in Overweight Patients with Metabolic Risk Factors", <i>Obesity</i> 14 (Suppl. 3):143S-149S (2006)
/B.C./	A110	Karasu et al., (2000) Practice Guideline for the Treatment of Patients with Major Depressive Disorder 1-78
/B.C./	A111	Koplan et al., "Preventing Childhood Obesity: Health in the Balance, Executive Summary", http://www.nap.edu/catalog/11015.html , 41 pages (2005)
/B.C./	A112	Krull, O. and Wunch, B., "Synthesis and Structure/NMDA Receptor Affinity Relationships of 1-Substituted Tetrahydro-3-benzazepines", <i>Bioorganic and Medicinal Chemistry</i> , 12, pp. 1439-1451, 2004
/B.C./	A113	Ladd et al., "Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 2-benzazepines, and 9-(Aminomethyl) fluorenes", <i>J. Med. Chem.</i> , Vol. 29:1904-1912 (1986)
/B.C./	A114	Lam RW, Levitt AJ (1999) (eds) Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder, Clinical & Academic Publishing, Vancouver, BC, Canada
/B.C./	A115	Lennon et al., "Azabenzocycloheptenones Part XVIII. Amines and amino-ketones of the tetrahydro-3-benzazepine-1-one series", <i>J. Chem. Soc. Perkin Transacts.</i> (1975) 7:622-626
/B.C./	A116	Linda D. Williams, Chemistry Demystified 123 (2003)
/B.C./	A117	Macdonald et al., "Design and synthesis of trans-3-(2-(4-(3-(3-(5-methyl-1,2,4-oxadiazolyl))-phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): A Potent and selective dopamine D.sub.3 Receptor Antagonist", <i>J. Med. Chem.</i> 46:4952-4964 (2003) American Chemical Society
/B.C./	A118	Moline et al., (2001) Expert Consensus Guideline Series - Treatment of Depression in Women 2001, March: 112-113
/B.C./	A119	Müller et al., (2006) <i>Trends in Pharmacological Sciences</i> , 27(9): 455 (Abstract)

Examiner Signature /Brenda Coleman/	Date Considered 09/22/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

** Structures only

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-043US1	Application No. 10/561,071
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit 1 624

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	A120	National Institute on Drug Abuse, Proceedings of the 41 st Annual Scientific Meeting (1979) pp. 356-401
/B.C./	A121	Navarro-Vazquez et al., "A study of aryl radical cyclization in enamionone esters", J. Org. Chem. 67:3213-20 (2002)
/B.C./	A122	Niendam et al., "Neurocognitive Performance and Functional Disability in the Psychosis Prodrome", <i>Schizophrenia Research</i> 84:100-111 (2006)
/B.C./	A123	Orioto et al., "Benzolactams—I: Alkylation of 1,2,4,5-tetrahydro-3-methyl-3h-3-benzazepin-2-one with sodium hydride and alkyl halide", <i>Tetrahedron</i> 36:1017-1021 (1980) Pergamon Press Ltd.
/B.C./	A124	Orito et al. (Hokkaido Daigaku Kogakubu Kenkyu Hokoku (1979), (96), 41-44
/B.C./	A125	Orito et al., "Total synthesis of pseudo type of protopine alkaloids", <i>Heterocycles</i> 14(1) 1980
/B.C./	A126	Pauvert et al., "Silver nitrate-promoted ring enlargement of 1-tribromomethyl-1,2-dihydro-and 1-tribromomethyl-1,2,3,4-tetrahydro-isoquinoline derivatives: application to the synthesis of the anti-analgal zalebradine", <i>Tetrahedron Letters</i> 44:4203-4206 (2003) Pergamon Press Ltd.
/B.C./	A127	Pawan et al., (1971) <i>British Journal of Pharmacology</i> , 41(2): 416P-417P (CAPLUS abstract)
/B.C./	A128	Pecherer et al., "The Synthesis of Some 7- and 7,8-substituted 2,3,4,5-tetrahydro-1H-3benzazepines", <i>J. Heterocyclic Chemistry</i> 8(5):779-783 (1971)
/B.C./	A129	Perry et al., "Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men", <i>BMJ</i> (1995) 310:560-564
/B.C./	A130	Piesla et al., (2001) <i>Schizophrenia Research</i> 49: 95
/B.C./	A131	Porras et al., (2002) <i>Neuropsychopharmacology</i> 26: 311-324
/B.C./	A132	Prous Science Integrity entry 156186 1 954
/B.C./	A133	Prous Science Integrity entry 354056 2003
/B.C./	A134	Rothman R.B., (1995) <i>Journal of Substance Abuse Treatment</i> , 12(6): 449
/B.C./	A135	Schlademan et al., "Synthesis of oxo- and 1-hydroxy-azobenzocycloalkanes", <i>J. Chem. Soc. Perkin Transact.</i> (1972) 2:213-215
/B.C./	A136	Schaffner et al., "Preventing Severe Mental Illnesses – New Prospects and Ethical Challenges", <i>Schizophrenia Research</i> 51:3-15 (2001)
/B.C./	A137	Smith et al., "Discovery and SAR of New Benzazepines as Potent and Selective 5-HT _{2C} Receptor Agonists for the Treatment of Obesity", <i>Bioorganic & Medicinal Chemistry Letters</i> 15(5):1467-1470 (2005)
/B.C./	A138	Smith, B. M. et al., "Discovery and Structure – Activity Relationship of (1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a Selective Serotonin 5-HT _{2C} Receptor Agonist for the Treatment of Obesity", [retrieved on 12/21/07]. Retrieved from the Internet. <URL: http://pubs.acs.org/journals/imcmr/index.html >.
/B.C./	A139	Tietz et al., "Efficient synthesis of 2, 3, 4, 5-tetrahydro-1H-3-benzazepines by intramolecular Heck reaction", <i>Synthesis</i> (1993) 9:876-880

Examiner Signature /Brenda Coleman/	Date Considered 09/22/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-043US1	Application No. 10/561,071
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit 1624
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/B.C./	A140	Tietze et al., "Efficient synthesis of 2,3,4,5-tetrahydro-1H-3-benzazepines by intramolecular heck reaction", Institut für Organische Chemie der Universität Göttingen, Tammannstraße 2, D-3400 Göttingen, Germany, received January 29, 1993.
/B.C./	A141	Tsuang et al., "Towards the Prevention of Schizophrenia", <i>Biol. Psychiatry</i> 48:349-356 (2000)
/B.C./	A142	Vink et al., "Risk Factors for Anxiety and Depression in the Elderly: A Review", <i>J. Affect. Disord.</i> , doi:10.1016/j.jad.2007.06.005, 16 pages (2007)
/B.C./	A143	Wise, R.A., (2000) <i>Neuron</i> , 26: 27-33
/B.C./	A144	Wisner et al., (2002) <i>N. Engl. J. Med.</i> , 347(3): 194-199
/B.C./	A145	Yoshinaga et al., "Prevention of Mildly Overweight Children from Development of More Overweight Condition", <i>Preventive Medicine</i> 38:172-174 (2004)
/B.C./	A146	International Search Report dated <u>November 22, 2004</u> for International Application No. PCT/US04/019670.

Examiner Signature /Brenda Coleman/	Date Considered 09/22/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	